Max India slips 5% after IRDAI approves sale of 51% stake in Max Bupa

Shares of Max India slipped 4.8 per cent to Rs 76.5 on the BSE on Wednesday after insurance regulator Insurance Regulatory & Development Authority of India (IRDAI) approved divestment of its 51 per cent stake in Max Bupa Health Insurance to Private Equity firm True North. The all-cash transaction announced in February 2019 valued Max Bupa at an enterprise value of Rs 1,001 crore.

With the deal getting regulatory approval, Max India will exit the health insurance business. In a regulatory filing on Tuesday, the firm informed the exchanges that the transaction is expected to be concluded within the next few weeks. READ FILING HERE

“The transaction will lead to a substantial cash inflow for Max India. As a part of our portfolio rebalancing exercise, we intend to utilize part of the proceeds to invest in both existing and new business opportunities," Mohit Talwar, Vice President, Max Group and MD, Max India said. 

Max Bupa is one of the leading standalone health insurance providers in India, and is a 51:49 joint venture between Max India Limited and Bupa Group.  In FY2019, the company reported Gross Written Premium of Rs. 947 Crore, an increase of 26 per cent.

At 9:55 AM, the stock was trading 4.2 per cent lower at Rs 76.95, as against a 0.1 per cent rise in the benchmark S&P BSE Sensex. 

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel